The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Synthetic Lethality-based Drugs and Targets Market Research Report 2024
Synopsis
In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen. Recent advances in biomarker research, including the development of companion diagnostics, in combination with modern molecular screening platforms, which include clustered regularly interspaced short palindromic repeats (CRISPR)- and RNA interference (RNAi)-based screening techniques, have led to the identification of a number of synthetically lethal gene pairs.
The global Synthetic Lethality-based Drugs and Targets market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Synthetic Lethality-based Drugs and Targets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Synthetic Lethality-based Drugs and Targets.
Report Scope
The Synthetic Lethality-based Drugs and Targets market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Synthetic Lethality-based Drugs and Targets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Synthetic Lethality-based Drugs and Targets companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
AstraZeneca
BeiGene
Clovis Oncology
GlaxoSmithKline
Pfizer
AtlasMedx
Chordia Therapeutics
IDEAYA Biosciences
Mission Therapeutics
Repare Therapeutics
Sierra Oncology
SyntheX Labs
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Medical Research Institution
Hospital and Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Synthetic Lethality-based Drugs and Targets companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen. Recent advances in biomarker research, including the development of companion diagnostics, in combination with modern molecular screening platforms, which include clustered regularly interspaced short palindromic repeats (CRISPR)- and RNA interference (RNAi)-based screening techniques, have led to the identification of a number of synthetically lethal gene pairs.
The global Synthetic Lethality-based Drugs and Targets market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Synthetic Lethality-based Drugs and Targets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Synthetic Lethality-based Drugs and Targets.
Report Scope
The Synthetic Lethality-based Drugs and Targets market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Synthetic Lethality-based Drugs and Targets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Synthetic Lethality-based Drugs and Targets companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
AstraZeneca
BeiGene
Clovis Oncology
GlaxoSmithKline
Pfizer
AtlasMedx
Chordia Therapeutics
IDEAYA Biosciences
Mission Therapeutics
Repare Therapeutics
Sierra Oncology
SyntheX Labs
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Medical Research Institution
Hospital and Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Synthetic Lethality-based Drugs and Targets companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Synthetic Lethality-based Drugs and Targets Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monotherapy
1.2.3 Combination Therapy
1.3 Market by Application
1.3.1 Global Synthetic Lethality-based Drugs and Targets Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Medical Research Institution
1.3.3 Hospital and Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Synthetic Lethality-based Drugs and Targets Market Perspective (2019-2030)
2.2 Synthetic Lethality-based Drugs and Targets Growth Trends by Region
2.2.1 Global Synthetic Lethality-based Drugs and Targets Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Synthetic Lethality-based Drugs and Targets Historic Market Size by Region (2019-2024)
2.2.3 Synthetic Lethality-based Drugs and Targets Forecasted Market Size by Region (2025-2030)
2.3 Synthetic Lethality-based Drugs and Targets Market Dynamics
2.3.1 Synthetic Lethality-based Drugs and Targets Industry Trends
2.3.2 Synthetic Lethality-based Drugs and Targets Market Drivers
2.3.3 Synthetic Lethality-based Drugs and Targets Market Challenges
2.3.4 Synthetic Lethality-based Drugs and Targets Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Synthetic Lethality-based Drugs and Targets Players by Revenue
3.1.1 Global Top Synthetic Lethality-based Drugs and Targets Players by Revenue (2019-2024)
3.1.2 Global Synthetic Lethality-based Drugs and Targets Revenue Market Share by Players (2019-2024)
3.2 Global Synthetic Lethality-based Drugs and Targets Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Synthetic Lethality-based Drugs and Targets Revenue
3.4 Global Synthetic Lethality-based Drugs and Targets Market Concentration Ratio
3.4.1 Global Synthetic Lethality-based Drugs and Targets Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Synthetic Lethality-based Drugs and Targets Revenue in 2023
3.5 Synthetic Lethality-based Drugs and Targets Key Players Head office and Area Served
3.6 Key Players Synthetic Lethality-based Drugs and Targets Product Solution and Service
3.7 Date of Enter into Synthetic Lethality-based Drugs and Targets Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Synthetic Lethality-based Drugs and Targets Breakdown Data by Type
4.1 Global Synthetic Lethality-based Drugs and Targets Historic Market Size by Type (2019-2024)
4.2 Global Synthetic Lethality-based Drugs and Targets Forecasted Market Size by Type (2025-2030)
5 Synthetic Lethality-based Drugs and Targets Breakdown Data by Application
5.1 Global Synthetic Lethality-based Drugs and Targets Historic Market Size by Application (2019-2024)
5.2 Global Synthetic Lethality-based Drugs and Targets Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Synthetic Lethality-based Drugs and Targets Market Size (2019-2030)
6.2 North America Synthetic Lethality-based Drugs and Targets Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Synthetic Lethality-based Drugs and Targets Market Size by Country (2019-2024)
6.4 North America Synthetic Lethality-based Drugs and Targets Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Synthetic Lethality-based Drugs and Targets Market Size (2019-2030)
7.2 Europe Synthetic Lethality-based Drugs and Targets Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Synthetic Lethality-based Drugs and Targets Market Size by Country (2019-2024)
7.4 Europe Synthetic Lethality-based Drugs and Targets Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size (2019-2030)
8.2 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Region (2019-2024)
8.4 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Synthetic Lethality-based Drugs and Targets Market Size (2019-2030)
9.2 Latin America Synthetic Lethality-based Drugs and Targets Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Country (2019-2024)
9.4 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size (2019-2030)
10.2 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Country (2019-2024)
10.4 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Synthetic Lethality-based Drugs and Targets Introduction
11.1.4 AbbVie Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Synthetic Lethality-based Drugs and Targets Introduction
11.2.4 AstraZeneca Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.2.5 AstraZeneca Recent Development
11.3 BeiGene
11.3.1 BeiGene Company Detail
11.3.2 BeiGene Business Overview
11.3.3 BeiGene Synthetic Lethality-based Drugs and Targets Introduction
11.3.4 BeiGene Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.3.5 BeiGene Recent Development
11.4 Clovis Oncology
11.4.1 Clovis Oncology Company Detail
11.4.2 Clovis Oncology Business Overview
11.4.3 Clovis Oncology Synthetic Lethality-based Drugs and Targets Introduction
11.4.4 Clovis Oncology Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.4.5 Clovis Oncology Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Synthetic Lethality-based Drugs and Targets Introduction
11.5.4 GlaxoSmithKline Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Synthetic Lethality-based Drugs and Targets Introduction
11.6.4 Pfizer Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 AtlasMedx
11.7.1 AtlasMedx Company Detail
11.7.2 AtlasMedx Business Overview
11.7.3 AtlasMedx Synthetic Lethality-based Drugs and Targets Introduction
11.7.4 AtlasMedx Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.7.5 AtlasMedx Recent Development
11.8 Chordia Therapeutics
11.8.1 Chordia Therapeutics Company Detail
11.8.2 Chordia Therapeutics Business Overview
11.8.3 Chordia Therapeutics Synthetic Lethality-based Drugs and Targets Introduction
11.8.4 Chordia Therapeutics Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.8.5 Chordia Therapeutics Recent Development
11.9 IDEAYA Biosciences
11.9.1 IDEAYA Biosciences Company Detail
11.9.2 IDEAYA Biosciences Business Overview
11.9.3 IDEAYA Biosciences Synthetic Lethality-based Drugs and Targets Introduction
11.9.4 IDEAYA Biosciences Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.9.5 IDEAYA Biosciences Recent Development
11.10 Mission Therapeutics
11.10.1 Mission Therapeutics Company Detail
11.10.2 Mission Therapeutics Business Overview
11.10.3 Mission Therapeutics Synthetic Lethality-based Drugs and Targets Introduction
11.10.4 Mission Therapeutics Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.10.5 Mission Therapeutics Recent Development
11.11 Repare Therapeutics
11.11.1 Repare Therapeutics Company Detail
11.11.2 Repare Therapeutics Business Overview
11.11.3 Repare Therapeutics Synthetic Lethality-based Drugs and Targets Introduction
11.11.4 Repare Therapeutics Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.11.5 Repare Therapeutics Recent Development
11.12 Sierra Oncology
11.12.1 Sierra Oncology Company Detail
11.12.2 Sierra Oncology Business Overview
11.12.3 Sierra Oncology Synthetic Lethality-based Drugs and Targets Introduction
11.12.4 Sierra Oncology Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.12.5 Sierra Oncology Recent Development
11.13 SyntheX Labs
11.13.1 SyntheX Labs Company Detail
11.13.2 SyntheX Labs Business Overview
11.13.3 SyntheX Labs Synthetic Lethality-based Drugs and Targets Introduction
11.13.4 SyntheX Labs Revenue in Synthetic Lethality-based Drugs and Targets Business (2019-2024)
11.13.5 SyntheX Labs Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
